Celadon Pharmaceuticals Plc (AIM:CEL)

Market Cap	3.10M
Revenue (ttm)	130.00K
Net Income (ttm)	-5.23M
Shares Out	68.85M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,600
Average Volume	40,485
Open	5.000
Previous Close	4.500
Day's Range	4.000 - 5.000
52-Week Range	2.210 - 105.000
Beta	-0.12
RSI	34.37
Earnings Date	May 6, 2025

About Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 27
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CEL

Financial Performance

In 2023, Celadon Pharmaceuticals's revenue was 75,000, an increase of 212.50% compared to the previous year's 24,000. Losses were -7.14 million, -58.01% less than in 2022.